drugset
drugset / Trial / NCT04432402

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

NCT04432402 ↗

Unknown 124 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.

Timeline

Start
2020-06-14
Primary completion
2022-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 10 mg Oral
Subject Lenalidomide Other / unclassified 15 mg Oral
Subject Lenalidomide Other / unclassified 20 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral
Background Gemcitabine Small molecule 1 g Intravenous
Background Oxaliplatin Small molecule 100 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma